Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting
Background: Peripheral artery disease (PAD) patients undergoing infrainguinal angioplasty with stenting suffer high rates of target lesion restenosis and ischemic events. Blood-based prognostic markers in these patients are currently limited. The IL-33/ST2-system is involved in atherothrombosis. Sol...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2020.605669/full |
| _version_ | 1828941493494087680 |
|---|---|
| author | Stefan Stojkovic Svitlana Demyanets Christoph W. Kopp Christian Hengstenberg Johann Wojta Johann Wojta Johann Wojta Beate Eichelberger Simon Panzer Thomas Gremmel Thomas Gremmel |
| author_facet | Stefan Stojkovic Svitlana Demyanets Christoph W. Kopp Christian Hengstenberg Johann Wojta Johann Wojta Johann Wojta Beate Eichelberger Simon Panzer Thomas Gremmel Thomas Gremmel |
| author_sort | Stefan Stojkovic |
| collection | DOAJ |
| description | Background: Peripheral artery disease (PAD) patients undergoing infrainguinal angioplasty with stenting suffer high rates of target lesion restenosis and ischemic events. Blood-based prognostic markers in these patients are currently limited. The IL-33/ST2-system is involved in atherothrombosis. Soluble ST2 has been proposed as a biomarker in patients with cardiovascular disease.Aim: To investigate the association of sST2 with platelet activation and monocyte tissue factor (TF) in 316 patients undergoing elective angioplasty and stenting for cardiovascular disease, and its predictive value for ischemic outcomes following infrainguinal angioplasty with stent implantation in 104 PAD patients within this cohort.Methods and Results: Circulating levels of sST2, platelet surface P-selectin, monocyte TF expression as well as soluble P-selectin were determined in 316 consecutive patients on dual antiplatelet therapy following angioplasty and stenting. sST2 was independently associated with soluble P-selectin (B = 6.4, 95% CI 2.0–10.7, p = 0.004) and TF expression (B = 0.56, 95% CI 0.02–1.1, p = 0.041) but not with platelet surface P-selectin (B = 0.1, 95% CI −0.1–0.3, p = 0.307) after adjustment for age, sex, clinical risk factors and inflammatory parameters. During the follow-up of 24 months, the primary endpoint occurred in 41 of 104 PAD patients (39.4%). However, circulating levels of sST2 did not predict the primary endpoint in PAD patients (HR 1.1, 95% CI 0.76–1.71, p = 0.527).Conclusion: sST2 is associated with soluble P-selectin and monocyte TF expression in atherosclerosis but not with ischemic outcomes following infrainguinal angioplasty with stent implantation for PAD. |
| first_indexed | 2024-12-14T03:37:38Z |
| format | Article |
| id | doaj.art-7684b9173ad74a409d253cb4067ba5d5 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-14T03:37:38Z |
| publishDate | 2020-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-7684b9173ad74a409d253cb4067ba5d52022-12-21T23:18:34ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-12-01710.3389/fcvm.2020.605669605669Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and StentingStefan Stojkovic0Svitlana Demyanets1Christoph W. Kopp2Christian Hengstenberg3Johann Wojta4Johann Wojta5Johann Wojta6Beate Eichelberger7Simon Panzer8Thomas Gremmel9Thomas Gremmel10Department of Internal Medicine II, Medical University of Vienna, Vienna, AustriaDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, AustriaDepartment of Internal Medicine II, Medical University of Vienna, Vienna, AustriaDepartment of Internal Medicine II, Medical University of Vienna, Vienna, AustriaDepartment of Internal Medicine II, Medical University of Vienna, Vienna, AustriaCore Facilities, Medical University of Vienna, Vienna, AustriaLudwig Boltzmann Institute for Cardiovascular Research, Vienna, AustriaDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, AustriaDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, AustriaDepartment of Internal Medicine II, Medical University of Vienna, Vienna, AustriaDepartment of Internal Medicine I, Cardiology and Intensive Care Medicine, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, AustriaBackground: Peripheral artery disease (PAD) patients undergoing infrainguinal angioplasty with stenting suffer high rates of target lesion restenosis and ischemic events. Blood-based prognostic markers in these patients are currently limited. The IL-33/ST2-system is involved in atherothrombosis. Soluble ST2 has been proposed as a biomarker in patients with cardiovascular disease.Aim: To investigate the association of sST2 with platelet activation and monocyte tissue factor (TF) in 316 patients undergoing elective angioplasty and stenting for cardiovascular disease, and its predictive value for ischemic outcomes following infrainguinal angioplasty with stent implantation in 104 PAD patients within this cohort.Methods and Results: Circulating levels of sST2, platelet surface P-selectin, monocyte TF expression as well as soluble P-selectin were determined in 316 consecutive patients on dual antiplatelet therapy following angioplasty and stenting. sST2 was independently associated with soluble P-selectin (B = 6.4, 95% CI 2.0–10.7, p = 0.004) and TF expression (B = 0.56, 95% CI 0.02–1.1, p = 0.041) but not with platelet surface P-selectin (B = 0.1, 95% CI −0.1–0.3, p = 0.307) after adjustment for age, sex, clinical risk factors and inflammatory parameters. During the follow-up of 24 months, the primary endpoint occurred in 41 of 104 PAD patients (39.4%). However, circulating levels of sST2 did not predict the primary endpoint in PAD patients (HR 1.1, 95% CI 0.76–1.71, p = 0.527).Conclusion: sST2 is associated with soluble P-selectin and monocyte TF expression in atherosclerosis but not with ischemic outcomes following infrainguinal angioplasty with stent implantation for PAD.https://www.frontiersin.org/articles/10.3389/fcvm.2020.605669/fullperipheral artery diseasesST2ischemic outcomesplatelet reactivitytissue factor |
| spellingShingle | Stefan Stojkovic Svitlana Demyanets Christoph W. Kopp Christian Hengstenberg Johann Wojta Johann Wojta Johann Wojta Beate Eichelberger Simon Panzer Thomas Gremmel Thomas Gremmel Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting Frontiers in Cardiovascular Medicine peripheral artery disease sST2 ischemic outcomes platelet reactivity tissue factor |
| title | Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting |
| title_full | Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting |
| title_fullStr | Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting |
| title_full_unstemmed | Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting |
| title_short | Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting |
| title_sort | association of soluble suppression of tumorigenesis 2 sst2 with platelet activation monocyte tissue factor and ischemic outcomes following angioplasty and stenting |
| topic | peripheral artery disease sST2 ischemic outcomes platelet reactivity tissue factor |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2020.605669/full |
| work_keys_str_mv | AT stefanstojkovic associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT svitlanademyanets associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT christophwkopp associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT christianhengstenberg associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT johannwojta associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT johannwojta associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT johannwojta associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT beateeichelberger associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT simonpanzer associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT thomasgremmel associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting AT thomasgremmel associationofsolublesuppressionoftumorigenesis2sst2withplateletactivationmonocytetissuefactorandischemicoutcomesfollowingangioplastyandstenting |